in case couldn't open/LDN Resolution

[Guest guest]

Representatives

Montpelier, Vermont

Joint House Resolution

J.R.H. 6

Joint resolution urging the Food and Drug Administration and the Multiple Sclerosis Society to study the efficacy of low dose naltrexone as a multiple sclerosis medication

Offered by: Representative Obuchowski of Rockingham

Whereas, multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) that damages the myelin sheath or insulating material that surrounds the nerve fibers in the brain, spinal cord, and optic nerves, and

Whereas, MS is characterized by attacks known as“flare-ups†or exacerbations which may be associated with plaques that prevent conduction of nerve impulses in the CNS, and

Whereas, MS is most likely to occur in persons ages 20 to 40, and women are two to three times as likely as men to contract the disease, and

Whereas, no two cases of MS are identical, and although some persons go for years with no symptoms, lesions may still be forming in the CNS, and

Whereas, in the United States, it is estimated approximately 350,000 individuals live with MS, and nearly 200 cases are diagnosed each week, and

Whereas, Vermont has the highest percentage of MS cases per capita of any state in the nation, and

Whereas, there is a variety of approved drugs for treating MS that have varying degrees of success, and

Whereas, one drug that is not currently approved for MS treatment, but in private use has reportedly been effective, is low dose naltrexone (LDN), and

Whereas, although neither the United States Food and Drug Administration (FDA) nor the National Multiple Sclerosis Society has conducted any official trials on the effectiveness of LDN, unofficial trials have shown a high degree of success in arresting the disease’s progression, although problems have occurred in individuals who are exposed to undue fatigue, heat or a febrile illness, and

Whereas, despite this caveat, the overwhelmingly positive reports on the impact of LDN for MS patients merits official clinical trials under the auspices of the National Multiple Sclerosis Society, now therefore be it

Resolved by the Senate and House of Representatives:

That the General Assembly urges both the United States Food and Drug Administration and the Multiple Sclerosis Society to conduct scientifically valid clinical trials to assess the effectiveness and ramifications of low dose naltrexone as a medication for treating multiple sclerosis, and be it further

Resolved: That the United States Congress appropriate funds to support the federal research, and be it further

Resolved: That a copy of this resolution be sent to Acting FDA Commissioner Dr. Lester Crawford, to President and Chief Executive Officer of the National Multiple Sclerosis Society, Dugan, to the members of the Vermont Congressional Delegation, and to Seth and Candi Sawyer in Westminster.

____________________________ Attested to:

Gaye R. Symington

Speaker of the House

____________________________ ____________________________

E. Dubie G. Milne

President of the Senate Clerk, House of Representatives

[Guest guest]



Hi Everyone,

What exactly is this for? Is this from the US or another country? Sounds like someone is trying to get LDN tested by the government. Great!

Aletha

[low dose naltrexone] in case couldn't open/LDN Resolution

Representatives

Montpelier, Vermont

Joint House Resolution

J.R.H. 6

Joint resolution urging the Food and Drug Administration and the Multiple Sclerosis Society to study the efficacy of low dose naltrexone as a multiple sclerosis medication

Offered by: Representative Obuchowski of Rockingham

Whereas, multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) that damages the myelin sheath or insulating material that surrounds the nerve fibers in the brain, spinal cord, and optic nerves, and

Whereas, MS is characterized by attacks known as“flare-ups†or exacerbations which may be associated with plaques that prevent conduction of nerve impulses in the CNS, and

Whereas, MS is most likely to occur in persons ages 20 to 40, and women are two to three times as likely as men to contract the disease, and

Whereas, no two cases of MS are identical, and although some persons go for years with no symptoms, lesions may still be forming in the CNS, and

Whereas, in the United States, it is estimated approximately 350,000 individuals live with MS, and nearly 200 cases are diagnosed each week, and

Whereas, Vermont has the highest percentage of MS cases per capita of any state in the nation, and

Whereas, there is a variety of approved drugs for treating MS that have varying degrees of success, and

Whereas, one drug that is not currently approved for MS treatment, but in private use has reportedly been effective, is low dose naltrexone (LDN), and

Whereas, although neither the United States Food and Drug Administration (FDA) nor the National Multiple Sclerosis Society has conducted any official trials on the effectiveness of LDN, unofficial trials have shown a high degree of success in arresting the disease’s progression, although problems have occurred in individuals who are exposed to undue fatigue, heat or a febrile illness, and

Whereas, despite this caveat, the overwhelmingly positive reports on the impact of LDN for MS patients merits official clinical trials under the auspices of the National Multiple Sclerosis Society, now therefore be it

Resolved by the Senate and House of Representatives:

That the General Assembly urges both the United States Food and Drug Administration and the Multiple Sclerosis Society to conduct scientifically valid clinical trials to assess the effectiveness and ramifications of low dose naltrexone as a medication for treating multiple sclerosis, and be it further

Resolved: That the United States Congress appropriate funds to support the federal research, and be it further

Resolved: That a copy of this resolution be sent to Acting FDA Commissioner Dr. Lester Crawford, to President and Chief Executive Officer of the National Multiple Sclerosis Society, Dugan, to the members of the Vermont Congressional Delegation, and to Seth and Candi Sawyer in Westminster.

____________________________ Attested to:

Gaye R. Symington

Speaker of the House

____________________________ ____________________________

E. Dubie G. Milne

President of the Senate Clerk, House of Representatives

[Guest guest]



VERMONT, at the moment, is a State of the United States

HOWEVER, they have petitioned to seceed from the union!

So if you ask this same question in a few years, the answer may very well be "another country" LOL

[low dose naltrexone] in case couldn't open/LDN Resolution

Representatives

Montpelier, Vermont

Joint House Resolution

[Guest guest]

Tisk, tisk, Aletha! Vermont is NOT another country, although New England can be idyllic. You are forgetting your childhood geography...

Who knows what became of this, or when it was dated. They can appeal, but it'll likely fall on deaf ears...

Rae

From: low dose naltrexone [mailto:low dose naltrexone ] On Behalf Of Aletha WittmannSent: Friday, January 06, 2006 8:43 AMlow dose naltrexone Subject: Re: [low dose naltrexone] in case couldn't open/LDN Resolution

Hi Everyone,

What exactly is this for? Is this from the US or another country? Sounds like someone is trying to get LDN tested by the government. Great!

Aletha

[low dose naltrexone] in case couldn't open/LDN Resolution

Representatives

Montpelier, Vermont

Joint House Resolution

J.R.H. 6

Joint resolution urging the Food and Drug Administration and the Multiple Sclerosis Society to study the efficacy of low dose naltrexone as a multiple sclerosis medication

Offered by: Representative Obuchowski of Rockingham

Whereas, multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) that damages the myelin sheath or insulating material that surrounds the nerve fibers in the brain, spinal cord, and optic nerves, and

Whereas, MS is characterized by attacks known as“flare-ups” or exacerbations which may be associated with plaques that prevent conduction of nerve impulses in the CNS, and

Whereas, MS is most likely to occur in persons ages 20 to 40, and women are two to three times as likely as men to contract the disease, and

Whereas, no two cases of MS are identical, and although some persons go for years with no symptoms, lesions may still be forming in the CNS, and

Whereas, in the United States, it is estimated approximately 350,000 individuals live with MS, and nearly 200 cases are diagnosed each week, and

Whereas, Vermont has the highest percentage of MS cases per capita of any state in the nation, and

Whereas, there is a variety of approved drugs for treating MS that have varying degrees of success, and

Whereas, one drug that is not currently approved for MS treatment, but in private use has reportedly been effective, is low dose naltrexone (LDN), and

Whereas, although neither the United States Food and Drug Administration (FDA) nor the National Multiple Sclerosis Society has conducted any official trials on the effectiveness of LDN, unofficial trials have shown a high degree of success in arresting the disease’s progression, although problems have occurred in individuals who are exposed to undue fatigue, heat or a febrile illness, and

Whereas, despite this caveat, the overwhelmingly positive reports on the impact of LDN for MS patients merits official clinical trials under the auspices of the National Multiple Sclerosis Society, now therefore be it

Resolved by the Senate and House of Representatives:

That the General Assembly urges both the United States Food and Drug Administration and the Multiple Sclerosis Society to conduct scientifically valid clinical trials to assess the effectiveness and ramifications of low dose naltrexone as a medication for treating multiple sclerosis, and be it further

Resolved: That the United States Congress appropriate funds to support the federal research, and be it further

Resolved: That a copy of this resolution be sent to Acting FDA Commissioner Dr. Lester Crawford, to President and Chief Executive Officer of the National Multiple Sclerosis Society, Dugan, to the members of the Vermont Congressional Delegation, and to Seth and Candi Sawyer in Westminster.

____________________________ Attested to:

Gaye R. Symington

Speaker of the House

____________________________ ____________________________

E. Dubie G. Milne

President of the Senate Clerk, House of Representatives

[Guest guest]

Hi Rae,

I was not sure that they meant the state of Vermont or not. I know a lot of times there are similar names for areas and towns in Canada, Australia and England.

That is great that someone has gotten it pushed all the way to that point in the state of Vermont.

Thanks

Aletha

[low dose naltrexone] in case couldn't open/LDN Resolution

Representatives

Montpelier, Vermont

Joint House Resolution

J.R.H. 6

Joint resolution urging the Food and Drug Administration and the Multiple Sclerosis Society to study the efficacy of low dose naltrexone as a multiple sclerosis medication

Offered by: Representative Obuchowski of Rockingham

Whereas, multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) that damages the myelin sheath or insulating material that surrounds the nerve fibers in the brain, spinal cord, and optic nerves, and

Whereas, MS is characterized by attacks known as“flare-ups” or exacerbations which may be associated with plaques that prevent conduction of nerve impulses in the CNS, and

Whereas, MS is most likely to occur in persons ages 20 to 40, and women are two to three times as likely as men to contract the disease, and

Whereas, no two cases of MS are identical, and although some persons go for years with no symptoms, lesions may still be forming in the CNS, and

Whereas, in the United States, it is estimated approximately 350,000 individuals live with MS, and nearly 200 cases are diagnosed each week, and

Whereas, Vermont has the highest percentage of MS cases per capita of any state in the nation, and

Whereas, there is a variety of approved drugs for treating MS that have varying degrees of success, and

Whereas, one drug that is not currently approved for MS treatment, but in private use has reportedly been effective, is low dose naltrexone (LDN), and

Whereas, although neither the United States Food and Drug Administration (FDA) nor the National Multiple Sclerosis Society has conducted any official trials on the effectiveness of LDN, unofficial trials have shown a high degree of success in arresting the disease’s progression, although problems have occurred in individuals who are exposed to undue fatigue, heat or a febrile illness, and

Whereas, despite this caveat, the overwhelmingly positive reports on the impact of LDN for MS patients merits official clinical trials under the auspices of the National Multiple Sclerosis Society, now therefore be it

Resolved by the Senate and House of Representatives:

That the General Assembly urges both the United States Food and Drug Administration and the Multiple Sclerosis Society to conduct scientifically valid clinical trials to assess the effectiveness and ramifications of low dose naltrexone as a medication for treating multiple sclerosis, and be it further

Resolved: That the United States Congress appropriate funds to support the federal research, and be it further

Resolved: That a copy of this resolution be sent to Acting FDA Commissioner Dr. Lester Crawford, to President and Chief Executive Officer of the National Multiple Sclerosis Society, Dugan, to the members of the Vermont Congressional Delegation, and to Seth and Candi Sawyer in Westminster.

____________________________ Attested to:

Gaye R. Symington

Speaker of the House

____________________________ ____________________________

E. Dubie G. Milne

President of the Senate Clerk, House of Representatives